Hepatitis B virus (HBV) is responsible for 50%-80% of cases of hepatocellular carcinoma (HCC) worldwide. Entecavir (ET) is a potent inhibitor of chronic HBV-DNA polymerase, inhibiting both the priming and elongation steps of viral DNA replication. Sorafenib (SO) has proven efficacy in prolonging survival in patients with advanced HCC. In this frontier report we discuss a possible way to optimize treatment outcomes in patients with HBV and HCC by treatment with ET and SO, on the basis of our practice and published evidence from the literature.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3627877 | PMC |
| http://dx.doi.org/10.3748/wjg.v19.i14.2141 | DOI Listing |
Publication Analysis
Top Keywords
sorafenib entecavir
4
entecavir dioscuri
4
dioscuri treatment
4
treatment advanced
4
advanced hepatocellular
4
hepatocellular carcinoma?
4
carcinoma? hepatitis
4
hepatitis virus
4
virus hbv
4
hbv responsible
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!